The main side effect of anti-CD47 antibody therapy is anemia (a decrease in the number of red blood cells), as the high level of CD47 protein expression on the surface of red blood cells (RBCs) prevents them from preterm elimination; conversely, RBCs under CD47 therapy get consumed [14–17]. This evidence concerns the gene CD47 and anemia.